SEC-sourced researchBeta
TSHA
Taysha Gene Therapies, Inc.
Company comparison ↗
Data passport
- CIK
- 0001806310
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Mar 19, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 8,333,000.0000 | Mar 19, 2026 |
| December 2025 | 9,773,000.0000 | Mar 19, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 9,773,000.0000 | -108,995,000.0000 | -93,090,000.0000 | 343,320,000.0000 | 96,382,000.0000 | Mar 19, 2026 |
| December 2024 | 8,333,000.0000 | -89,298,000.0000 | -81,225,000.0000 | 160,364,000.0000 | 88,839,000.0000 | Mar 19, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $9.77M | December 2025 | Mar 19, 2026 | 10-K |
| Previous period revenueRevenues | $8.33M | December 2024 | Mar 19, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$109M | December 2025 | Mar 19, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$93.09M | December 2025 | Mar 19, 2026 | 10-K |
| Total assetsAssets | $343.32M | December 2025 | Mar 19, 2026 | 10-K |
| Total liabilitiesLiabilities | $96.38M | December 2025 | Mar 19, 2026 | 10-K |